Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03297606 |
TitleCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Phase
Phase 2
|
Date Added 2017-09-29 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04948034 |
TitleThe Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | Phase
Phase 2
|
Date Added 2021-07-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04607421 |
TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) | Phase
Phase 3
|
Date Added 2020-10-29 |
Location
Arizona, United States
California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT02856425 |
TitleTrial Of Pembrolizumab And Nintedanib | Phase
Phase 1
|
Date Added 2016-08-04 |
Location
France
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef |
Tags
MSS/ MMRp
|
| NCT ID NCT04659382 |
TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-12-09 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, TheraSphere, XELOX |
Tags
MSS/ MMRp
|
| NCT ID NCT03950154 |
TitleStudy of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2019-05-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03947385 |
TitleStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase
Phase 1, Phase 2
|
Date Added 2019-05-13 |
Location
California, United States
New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Binimetinib, Crizotinib, IDE196 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03829462 |
TitleAssessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients | Phase
Phase 3
|
Date Added 2019-02-04 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Irinotecan, Regorafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04014530 |
TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | Phase
Phase 1
|
Date Added 2019-07-10 |
Location
Netherlands
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Ataluren + Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT04096417 |
TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | Phase
Phase 2
|
Date Added 2019-09-19 |
Location
Arizona, United States
Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pemigatinib |
Tags
MSS/ MMRp
|
